You are viewing the site in preview mode
Skip to main content
|
Parameter
|
RMSE, mean (SD)
|
MAPE, %
|
Bias
|
LoA
|
RMSE, mean (SD)
|
MAPE, %
|
Bias
|
LoA
|
|---|
|
SNP
|
PLHIV
|
|---|
|
Spatial parameters
|
|
Step length (cm)
|
3.22 (1.63)
|
1.66
|
− 1.05
|
− 5.83; 3.72
|
4.38 (2.01)
|
1.07
|
− 0.74
|
− 4.95; 3.47
|
|
Normalized step length
|
0.04 (0.02)
|
1.66
|
− 0.01
|
− 0.07; 0.04
|
0.05 (0.02)
|
1.07
|
− 0.01
|
− 0.05; 0.04
|
|
Stride length
|
4.46 (3.51)
|
2.51
|
− 3.26
|
− 11.45; 4.92
|
4.46 (2.62)
|
2.28
|
− 2.95
|
− 10.68; 4.78
|
|
Normalized stride length
|
0.05 (0.04)
|
2.51
|
− 0.04
|
− 0.13; 0.05
|
0.05 (0.03)
|
2.28
|
− 0.03
|
− 0.11; 0.05
|
|
Temporal parameters
|
|
Cadence (steps/min)
|
6.93 (4.41)
|
0.39
|
0.49
|
− 5.55; 6.54
|
6.15 (4.86)
|
0.18
|
0.01
|
− 4.75; 5.00
|
|
Stance time (s)
|
0.02 (0.01)
|
1.22
|
0.01
|
− 0.03; 0.04
|
0.03 (0.02)
|
1.06
|
0.01
|
− 0.04; 0.05
|
|
Step time (s)
|
0.03 (0.02)
|
0.12
|
< 0.00
|
− 0.03; 0.03
|
0.03 (0.02)
|
0.17
|
< 0.00
|
− 0.02; 0.02
|
|
Single support time (s)
|
0.02 (0.01)
|
1.21
|
− 0.01
|
− 0.03; 0.02
|
0.02 (0.01)
|
1.43
|
− 0.01
|
− 0.02; 0.01
|
|
Double support time (s)
|
0.03 (0.01)
|
7.40
|
0.01
|
− 0.04; 0.06
|
0.03 (0.03)
|
5.79
|
0.01
|
− 0.05; 0.07
|
|
Temporophasic parameters
|
|
Stance percentage (%GC)
|
1.72 (0.39)
|
0.98
|
0.57
|
− 1.37; 2.51
|
1.97 (1.23)
|
1.13
|
0.69
|
− 2.00; 3.43
|
|
Single support percentage (%GC)
|
2.44 (1.35)
|
1.37
|
− 0.57
|
− 3.53; 2.39
|
2.31 (1.40)
|
1.26
|
− 0.50
|
− 3.24; 2.24
|
|
Double support percentage (%GC)
|
3.01 (1.14)
|
6.96
|
1.14
|
− 3.58; 5.86
|
2.68 (2.29)
|
5.69
|
1.18
|
− 4.14; 6.51
|
|
Temporospatial parameters
|
|
Gait speed (m/s)
|
0.04 (0.03)
|
2.68
|
− 0.03
|
− 0.11; 0.04
|
0.04 (0.03)
|
2.13
|
− 0.03
|
− 0.10; 0.05
|
|
Normalized gait speed
|
0.01 (0.01)
|
2.68
|
− 0.01
|
− 0.04; 0.01
|
0.01 (0.01)
|
2.13
|
− 0.01
|
− 0.03; 0.02
|
- MAPE mean absolute percentage error, GC gait cycle, LoA limits of agreement, PLHIV people living with HIV-1 infection, RMSE root-mean-square error, SNP HIV-seronegative participants